Zoptarelin Doxorubicin

Colorectal cancer (CRC) is the third most deadly cancer diagnosed in both men and women. 5-Fluorouracil (5-FU) treatment frequently causes the CRC cells to become chemoresistance, which has a negative impact on prognosis. Using bioinformatic techniques, this work describes important genes and biological pathways linked to 5-FU resistance in CRC cells. In our studies, a 5-FU-resistant HCT 116 cell line exhibiting elevated TYMS was created and validated using various tests. Bioinformatic studies were conducted to determine which differentially expressed genes (DEGs) were responsible for the establishment of 5-FU resistance in the same cell line. After screening 3949 DEGs from the two public datasets (GSE196900 and GSE153412), 471 overlapping DEGs in 5-FU-resistant HCT 116 cells were chosen. These overlapping DEGs were used to build the PPI network, and a major cluster module containing 21 genes was found. Subsequently, using three topological analysis algorithms, 10 hub genes were identified, which included HLA-DRA, HLA-DRB1, CXCR4, MMP9, CDH1, SMAD3, VIM, SYK, ZEB1, and SELL. Their roles were ascertained by utilizing Gene Ontology keywords and pathway enrichment studies. Our results also demonstrated that the miRNA and transcription factors (TFs) that had the strongest connection with the hub genes were hsa-mir-26a-5p, hsa-mir-30a-5p, RELA, and NFKB1. Ultimately, 84 FDA-approved drugs that target those hub genes were found to potentially treat 5-FU resistance CRC. Our research's findings increase our understanding of the fundamental factors that contribute to the prevalence of 5-FU resistance CRC, which could ultimately assist in the identification of valuable malignancy biomarkers and targeted treatment approaches based on key regulatory pathways.

Curcumin, originally isolated as natural product from the rhizome of Curcuma longa L., is widely known for its anticancer properties. However, the clinical application of curcumin is still limited due to its poor absorption and rapid metabolism. In this study, structural modification of curcumin by introducing active small organic acids into its pyrazole ring intermediate, was employed to yield five curcumin derivatives 5a-5e. All the target compounds were characterised by ¹H NMR,¹³C NMR and ESI-MS. Biological evaluation through the CCK-8 method indicated that nearly all these derivatives displayed higher proliferation inhibitory effect on A549 cells than that of curcumin. Among them, 5d bearing biotin moiety exhibited even stronger cytotoxicity action (2.25 μmol/L) than the positive control drug Doxorubicin (3.99 μmol/L) and therefore became the most promising lead compound for further investigation. Our findings provided a potential approach for the structural optimisation of curcumin derivatization in cancer treatment.